Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

BACKGROUND: Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induce HER2-specific antibodies which correlate with improved surviv...

Descripción completa

Detalles Bibliográficos
Autores principales: Norton, Nadine, Fox, Nicholas, McCarl, Christie-Ann, Tenner, Kathleen S., Ballman, Karla, Erskine, Courtney L., Necela, Brian M., Northfelt, Donald, Tan, Winston W., Calfa, Carmen, Pegram, Mark, Colon-Otero, Gerardo, Perez, Edith A., Clynes, Raphael, Knutson, Keith L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000975/
https://www.ncbi.nlm.nih.gov/pubmed/29898752
http://dx.doi.org/10.1186/s13058-018-0989-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000975/
https://www.ncbi.nlm.nih.gov/pubmed/29898752
http://dx.doi.org/10.1186/s13058-018-0989-8

Ejemplares similares